© Provided by The Financial Express Mayur, founder and MD of h2e Power, said they are completing the detailing on paper before embarking on implementing the project.
The world's largest vaccine maker, Serum Institute of India (SII), could soon become the world’s first company to produce a 'Green Vaccine'. The vaccine major firm is also aspiring to be the first `Net Zero’ pharma company in the world.
Achieving Net Zero state would mean reduction of emissions from all sources to zero. Adar Poonawalla-backed cleantech startup, h2e Power Systems, will be powering SII’s transition to renewable and green energy. Pune-based h2e Power is India’s first homegrown green hydrogen and fuel cell company. h2e is now working on the SII blueprint to achieve Net Zero status. h2e is founded by Siddharth R Mayur, Amarnath Chakradeo and Bhavana S Mayur and incubated at IIT-SINE. Poonawalla invested in the company and acquired a 50% stake early this year and it is now a Poonawalla Group company.
Mayur, founder and MD of h2e Power, said they are completing the detailing on paper before embarking on implementing the project. "We expect to start implementation by mid-2021 and complete phase-I by December 2021. The plan is to make them Net-Zero by 2024-2025," said Mayur.
By March 2021, they will have clarity on capacity, investments, savings and emission reduction and there will be substantial gains, he said. Take, for example, SII spends a lot of energy on storing vaccines and they can go to a stage when they will not need to use any fossil fuel for the cooling needs and have no emissions, Mayur said.
h2e is betting on fuel cells and hydrogen becoming as common as wind and solar energy in the coming years. He expects the market in India would take two to three years to develop. "India is on the cusp of a big energy revolution. With technologies like the fuel cell and waste to hydrogen India can become 100% energy independent," Mayur said.
"Hydrogen and fuel cells are going to be a key driver in achieving this goal. With heaps of domestic, agriculture and industrial waste piling up all around, we have great potential to convert them into renewable hydrogen," he said.
h2e is working out multiple modules for SII that would include solar, hydrogen, synthetic gas, JP8 Fuel. They plan to use the hydrogen / Syngas for their process plants and electricity purposes, using fuel cell technology for the chillers and vaccine transport vehicles, Mayur said. h2e has tied up with US-based Ways2H, a waste to hydrogen company, to produce green hydrogen from waste in India.
Poonawalla had helped h2e Power acquire a Swiss fuel cell specialist, Hexis AG. h2e Power also acquired mPower GmbH in Germany. Poonawalla, who is also chairman of h2e Power, had said: "We intend to reach every home, every commercial establishment and every city with our hydrogen and fuel cell technologies. We are building a large manufacturing capacity in Pune for Indian and global markets."
Fuel cell technology is pegged to be the energy alternative for the future. The company plans to install its first plant in Pune. According to Mayur, this would be the largest fuel cell facility in the country and would have a capacity of 100 MW, Mayur said. h2e will produce hydrogen for fuel cell electric vehicles and also set up a downstream facility to produce fuels such as methanol/kerosene.
Source - MSN News
Adar Poonawalla awarded 'Business Leader of the Year' 2023 by the International Advertising Association (IAA) India Chapter
Cyrus Poonawalla Group appoints Keki Mistry as Strategic Advisor to all the Financial Services Ventures led by Adar Poonawalla
R21/Matrix-M™ malaria vaccine developed by University of Oxford receives regulatory clearance for use in Ghana
Department of Biotechnology announces the scientific completion of India's first qHPV vaccine ‘CERVAVAC’
Adar Poonawalla, CEO, Serum Institute of India, receives the award for the Outstanding Business Leader of the Year
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.